References
  1. 2018 Classification. http://www.issva.org/classification. Published 2018. Accessed October 1, 2020.
  2. Vikkula M, Boon LM, Mulliken JB. Molecular genetics of vascular malformations. Matrix Biol. 2001;20:327-335.
  3. Boom LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies.Clin Plast Surg. 2011;38:7-19.
  4. Hassanein AH, Mulliken JB, Fishman SJ, Alomari AI, Zurakowski D, Greene AK. Venous malformations: risk of progression during childhood and adolescence. Ann Plast Surg . 2012;68:198-201.
  5. Colletti G, Ieraradi IM. Understanding venous malformations of the head and neck: a comprehensive insight. Med Oncol . 2017;34(3): 896-899.
  6. Sidney LE, Branch MJ, Dunphy SE. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cell . 2014;32(6):1380-1389.
  7. Gupta A, Kozakewich H. Histopathology of vascular anomalies.Clin Plastic Surg. 2011;38:31-44.
  8. Laurian C, Cerceau P, Paraskevas N, et al. Intramuscular venous malformations of the calf: surgical treatment outcomes of 57 patients.Phlebology . 2020;35(8):597-604.
  9. Behravesh S, Yakes W, Gupta N, et al. Venous malformations: clinical diagnosis and treatment. Cardiovasc Diagn Ther . 2016;6(6):557-569.
  10. Cahill AM, Nijs EL. Pediatric vascular malformations: pathophysiology, diagnosis and role of interventional radiology. Cardiovas Intervent Radiol . 2011;34(4):691-704.
  11. Bagrodia N, Defnet AM, Kandel JJ. Management of lymphatic malformations in children. Curr Opin Pediatr . 2015;27(3):356-363.
  12. Nguyen HL, Boon LM, Vikkula M. Genetics of vascular malformations.Seminar Pediatr Surg . 2014;23:221-226.
  13. Vikkula M, Boon LM, Carraway KL et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.Cell . 1996;87(8):1181-1190.
  14. Limaye N, Wouters V, Ubelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK causes solitary and multiple sporadic venous malformations. Nat Genet . 2009;41(1):118-124.
  15. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinase Tie-1 and Tie-2 in blood vessel formation.Nature. 1995;376:70-74.
  16. Dubois J, Soulez G, Olivia VL, et al. Soft tissue venous malformations in adult patients: imaging and therapeutic issues.Radiographics . 2001;21(6):1519-1531.
  17. Colletti G, Valassina D, Bertossi D, et al. Contemporary management of venous malformations. J Oral Maxillofac Surg . 2014;72(3):510-528.
  18. Johnson CM, Nararro OM. Clinical and sonographic features of pediatric soft tissue vascular anomalies part 2: vascular malformations.Pediatr Radiol . 2017;47(9):1196-1208
  19. Eivazi B, Fasunla AJ, Guldner C, Masberg P, Werner JA, Teymoortash A. Phleboliths from venous malformations of the head and neck.Phlebology . 2013;28(2):86-92.
  20. Trop I, Dubois J, Guibaud L, et al. Soft tissue venous malformations in pediatric and young adult patients: diagnosis with Doppler ultrasound. Radiology . 1999;212(3):841-845.
  21. Flors L, Leiva-Salinas C, Maged IM, et al. MR imaging of soft-tissue vascular malformations: diagnosis, classification, and therapy follow-up. Radiographics . 2011;31:1321-1340.
  22. Restrep R. Multi-modality imaging of vascular anomalies. Pediatr Radiol . 2013;43:141-154.
  23. Langbrock GB, Horbach SE, Vanderleuten CJM, et al. Compression therapy for congenital low flow vascular malformations of the extremities- a systemic review. Phlebology . 2018;33(1):5-13.
  24. Wang SK, Drucker NA, Gupta AK, et al. Diagnosis and management of Klippel-Trenaunay syndrome. J Vasc Surg Venous Lymphat Disord . 2017;5(4):587-595.
  25. James CA, Braswell LE, Wright LB, et al. Pre-operative sclerotherapy of facial venous malformations: impact on surgical parameters and long term follow-up. J Vasc Interv Radiol . 2011;22:953-960.
  26. Odeyinde SO, Kangesu L, Badran M, et al. Sclerotherapy for vascular malformations: complications and a review of techniques to avoid.J Plast Reconstr Aesthet Surg . 2013;66:215-223.
  27. Hage AN, Chick JF, Srinivasa J, et al. Treatment of venous malformations: the data, where we are, how it is done. Tech Vasc Interv Radiol . 2018;21:45-54.
  28. Pimpalwar S. Vascular malformations: approach by interventional radiology. Semin Plast Surg . 2014;28(2):91-193.
  29. Greinwald JH, Burke DK, Sato Y, et al. Treatment of lymphangiomas in children: an update of picibanil (OK-432) sclerotherapy.Otolaryngol Head Neck Surg . 1999;121(4):381-387.
  30. Tu JH, Do HM, Patel V, et al. Sclerotherapy for lymphatic malformations of the head and neck. Journal of Neurointerventional Surgery. 2017;9:1023-1026.
  31. Albanese G, Kondo KL. Pharmacology of sclerotherapy. Semin Intervent Radiol. 2010;27(4): 391-399.
  32. Zhang J, Li HB, Zhou SY, et al. Comparison between absolute ethanol and bleomycin for the treatment of venous malformations in children.Exp Ther Med. 2013;6(2):305-309.
  33. Schaffer M, Walz E, Stormer K, et al. Health link: bleomycin alert. Children’s oncology group. 2013.
  34. de Maria L, Sanctis PD, Balakrishnan K, et al. Sclerotherapy for lymphatic malformations of the head and neck: systemic review and meta-analysis. J Vasc Surg Venous Lymphat Disord . 2020;8(1):154-164.
  35. Zhong LP, Ow A, Yang WJ, et al. Surgical management of solitary venous malformation in the midcheek region. Oral Surg Oral Med . 2012;114:160-166.
  36. Loose DA. Surgical management of venous malformations.Phlebology. 2007;22(6):276-282.
  37. Defnet AM, Bagrodia N, Hernandez SL et al. Pediatric lymphatic malformations: evolving understanding and therapeutic options.Pediatr Surg Int. 2016;32:425-433.
  38. Seront E, van Damme AN, Boon LA, et al. Rapamycin and treatment of venous malformations. Curr Opin Hematol . 2019;26:185-192.
  39. Hammill AM, Wentzel MS, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer . 2011;57(6):1018-1024.
  40. Hung JWS, Leung MWY, Liu CSW et al. Venous malformations and localized intravascular coagulopathy in children. Eur J Pediatr Surg . 2017;27(02):181-184.
  41. Dompartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulation with venous malformations. Arch Dermatol . 2008;144(7):873-877.
  42. Zhou KY, Russell S, Wargon O, Adams S. Localized intravascular coagulation complicating venous malformations in children: associations and therapeutic options. J Pediatr Child Health . 2017;53(8):737-741.
  43. Han YY, Sun LM, Yuan SM. Localized intravascular coagulation in venous malformations: a system review. Phlebology . 2021;36(1):38-42.
  44. Mason KP, Neufield EJ, Karian VE, et al. Coagulation abnormalities in pediatric and adult patients after sclerotherapy or embolization of vascular anomalies. Am J Roentgenol . 2001;177(6):1359-1363.
  45. Griffith CH, Herod J. Anesthesia for massive venous malformation and disseminated intravascular coagulation: strategies for minimizing blood loss: a case report. Ped Anesth Crit Care . 2015;3(1):22-25.
  46. Mazoyer O, Enjolras C, Laurian C, et al. Coagulation abnormalities associated with extensive venous malformations of the limb: differentiation from kasabach-merritt syndrome. Clin Lab Haematol . 2002;24(4):243-251.
  47. Sing AC, Webb JL, Low DW, Chen AE. Pulmonary emboli associated with isolated lower-extremity venous malformation: a case report.Pediatr Emerg Care . 2013;29(3):371-373.
  48. Hautier-Mazeereeuq J, Syed S, Leisner RI, Harper JI. Extensive venous/lymphatic malformations causing life threatening hematological complications. Br J Dermatol . 2007;157(3):558-563.
  49. Nakano T, Zeinati C. Venous Thromboembolism in pediatric vascular anomalies. Front Pediatr . 2015;5(158):1-6.
  50. Sepulveda P, Zavala A, Zuniga P. Factors associated with thrombotic complications in pediatric patients with vascular malformations. J Pediatr Surg . 2016;52(3):400–410.
  51. Nguygen JT, Koerper MA, Hess CP, et al. Aspirin therapy in venous malformations: a retrospective cohort study of benefits, side effects, and patient experiences. Ped Derm . 2014;31(5):556-560.
  52. Adams DM. Special considerations in vascular anomalies: hematologic management. Clin Plast Surg . 2011; 38(1):153–160.
  53. Vandenbriele C, Vanassche T, Peetermans M, Verhamme P, Peerlinck K. Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation. J Thromb Thrombolysis . 2014;38(1):121-123.
  54. Mack JM, Richter GT, Crary SE. Effectiveness and safety of treatment with direct oral anticoagulant rivaroxaban for slow-flow vascular malformations: a case series. Lymphat Res Biol . 2018;16(3):278-281.
  55. The American Society of Pediatric Hematology/Oncology. Vascular Anomalies Special Interest Group. Chicago, IL: The American Society of Pediatric Hematology/Oncology; 2015. Available from: http://aspho.org/membership/special‐interest‐groups/vascular‐anomalies. Accessed August 1, 2020.
  56. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr . 2015;166(4):1048-1054.
  57. Blesinger H, Kaulfub S, Aung T, et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. PLOS One . 2018;13(7):1-18.
  58. De Serres LM, Sie KC, Richardson MA, et al. Lymphatic malformations of the head and neck: a proposal for staging. Arch Otolaryngol Head Neck Surg. 1995;121(5):577-582.
  59. Boardman SJ, Cochrange LA, Roebuck D, et al. Multimodality treatment of pediatric lymphatic malformations of the head and neck using surgery and sclerotherapy. Arch Otolaryngol Head Neck Surg . 2010;136(3):270-276.
  60. Elluru RG, Balakrishnan K, Padua HM, et al. Lymphatic malformations: diagnosis and treatment. Seminars in Ped Surg . 2014;23(4):178-185.
  61. White CL, Olivieri B, Restrep R, et al. Low flow vascular malformation pitfalls: from clinical examination to practical imaging evaluation.Am J of Rotentgenology . 2016;206(5):940-951.
  62. Ma J, Biao R, Lou F, et al. Diagnosis and surgical treatment of cervical macrocystic lymphatic malformation in infants. Exp Ther Med. 2017;14(2):1293-1298.
  63. Flis CM, Connor SE. Imaging of head and neck venous malformations.Eur Radiol . 2005;15:2185-2193.
  64. Greene AK, Perlyn CA, Alomari AI. Management of lymphatic malformations. Clin Plast Surg . 2011;38:75-82.
  65. Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: a review of current treatment. Otolaryngol Head Neck Surg . 2010;142(6):795-803.
  66. Strychowsky JE, Rahbar R, O’Hare MJ, Padua H, Trenor CC. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope . 2018;128(1):269-276.
  67. Mohan AT, Adams S, Adams K, et al. Intralesion injection of bleomycin in management of low flow vascular malformations in children. J Plast Surg and Hand Surg . 2015;49(2):116-120.
  68. Chaudry G, Guevara CJ, Rialon KL, et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation.Cardiovasc Intervent Radiol. 2014;37:1476-1481.
  69. Niazi TN, Klimo P Jr, Anderson RC, Raffel C. Diagnosis and management of arteriovenous malformations in children.Neurosurg Clin N Am . 2010;21(3):443-456.
  70. El-Ghanem M , Kass-Hout T, Kass-Hout O et al. Arteriovenous Malformations in the Pediatric Population: Review of the Existing Literature. Interv Neurol.  2016;5(3-4):218-225.
  71. Ajiboye N, Chalouhi N, Starke RM, et al. Cerebral AVM: evaluation and management. Scientific World Journal . 2014. 1-6.
  72. Dinc N, Won SY, Quick-Weller J, Berkefeld J, Seifert V, Marquardt G. Prognostic variables and outcome in relation to different bleeding patterns in arteriovenous malformations. Neurosurg Rev . 2019;42(3):731-736.
  73. Giordano P, Lenato GM, Suppressa P, et al. Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children.J Pediatr . 2013;163(1):179-86.e1-3.
  74. Liao Y, Chen K-H, Huang G-Y, Song W. Pulmonary arteriovenous malformations presenting as refractory heart failure. J Thorac Dis . 2014;6(9): E169–E172.
  75. Bouwman FCM, Botden SMBI, Verhoeven BH, et al. Treatment Outcomes of Embolization for Peripheral Arteriovenous Malformations. J Vasc Interv Radiol . 2020;1(11):1801-1809.
  76. Priemer DS, Vortmeyer AO, Zhang S, Chang HY Curless K. Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation. Hum Pathol . 2019;89:33-39.
  77. Lekwuttikam R, Lim YH, Admani S Choate KJ, Teng J. Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child.Jama Dermatol 2019;155(2):256-257.
  78. Phelps EA, Cooke D, Frieden IJ,  Zapala MA,  Fullerton HJ , Shimano KA.  Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy. Pediatrics . 2020;146(3):e3206.
  79. Hill H, Chick JF Hage. A, Srinivasa R. N-butyl cyanoacrylate embolotherapy: techniques, complications, and management.Diagn Interv Radiol.  2018; 24(2): 98–103.
  80. Gabeff R, Boccara O, Soupre V, et al. Efficacy and Tolerance of Sirolimus (Rapamycin) for Extracranial Arteriovenous Malformations in Children and Adults. Acta Derm Venereol . 2019;99(12):1105-1109.
  81. Cheliah MP, Do H, Zinn Z, et al. Management of Complex Arteriovenous Malformations Using a Novel Combination Therapeutic Algorithm.JAMA Dermatol.  2018;154(11):1316-1319.